CAMBRIDGE, MASSACHUSETTS — Skylark Bio announced that it will present new preclinical data for SKY-PEN, its Pendrin gene therapy program targeting SLC26A4-related hearing loss, at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting....
No actionable change — this is a preclinical press release with no human data yet; audiologists cannot apply these findings to patient care.
Gene therapies targeting specific genetic causes of hearing loss represent a potential future treatment paradigm that could shift audiology from management to cure for select patient populations.
- 01Skylark Bio will present preclinical (animal/lab) data for SKY-PEN at ASGCT 2026.
- 02SKY-PEN targets SLC26A4 (Pendrin), a gene whose mutations cause a form of genetic hearing loss.
- 03Data is preclinical only — no human clinical trials have been announced.
- 04Presentation at ASGCT signals growing industry interest in inner-ear gene therapy.
- 05No efficacy or safety data in humans is available at this stage.
SKY-PEN is a gene therapy targeting the Pendrin (SLC26A4) gene for treatment of genetic hearing loss.
press releaseunclearSkylark Bio will present new preclinical data for SKY-PEN at ASGCT 2026.
press releasesupported